MARKET WIREYahoo • 1h ago
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earningsBiopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect.
Why JAZZ Stock advanced +1.35% Today — RQD Quant Desk Flash
$207.83 +1.35% NASDAQ • Public Delayed / 60s Snapshot
Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C- • HOLD / WATCH
Cap $13.49B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+1.4% Base Target
WHALE OPTIONS TUG-OF-WAR:55% Call Buyers ($2.5M)
45% PutsMax Pain: $204.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why JAZZ Stock advanced +1.35% Today — RQD Quant Desk Flash
Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) advanced +1.35% to $207.83 as options desks priced 55% call premium vs. 45% put protection around the $204 max-pain magnet. Solid 41% profit margin (-5% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 57% of its 52-week range ($128.8 – $266.38) with RSI-14 at 46.4 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $2.5M in bullish call flow vs. $2.0M in put flow (Put/Call 0.81x, implied earnings swing ±7.2%).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 44% gross margin and $1.3B annual free cash flow.
Live JAZZ Headlines & Catalysts
CATALYSTYahoo • 1d ago
3 Biotech Stocks With Upside Of Up To 80%Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, hig
MARKET WIREYahoo • 1d ago
With Setara, the team behind Actio opens its second actThe fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
MARKET WIREYahoo • 1d ago
Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion IndicationsSAN DIEGO, October 30, 2026--Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90
CATALYSTBenzinga • 3d ago
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.
CATALYSTYahoo • 4d ago
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineJazz Pharmaceuticals' strategy is starting to pay dividends.
CATALYSTYahoo • 4d ago
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseUltragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREBenzinga • 5d ago
Jazz Pharmaceuticals Estimates $755M Pre-Tax Acquired IPR&D Charge From Actio Biosciences Acquisition; Expected $11.00 Negative Impact On Both GAAP And Adjusted EPS In Q3 2026Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition In connection with its acquisition of Actio Biosciences, Inc., a Delaware corporation ("Actio"), which was completed on September
CATALYSTYahoo • 5d ago
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forJazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREYahoo • 8d ago
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live JAZZ Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
JAZZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.38%📐 HORIZONTAL RANGE
2026-10-30O $209.6H $216.6L $209.4C $216.0VOL 1.22M
RES: $291.6SUP: $201.5SMA50: $232.0SMA200: $216.6
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
JAZZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
27.7%/yr Implied 5Y Growth
vs. +4.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on JAZZ today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for JAZZ. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JAZZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
JAZZ Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is JAZZ stock moving today?
Why JAZZ Stock advanced +1.35% Today — RQD Quant Desk Flash. Solid 41% profit margin (-5% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.